# KEYNOTE-590 (NCT03189719)

> First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab
- Indication: previously untreated advanced or metastatic esophageal cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03189719
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Esophageal Neoplasms
- Interventions: Pembrolizumab; Placebo; Cisplatin; 5-FU
- Enrollment: 749
- Primary outcome: Overall Survival (OS) in Participants With Esophageal Squamous Cell Carcinoma (ESCC) Whose Tumors Are Programmed Cell Death-Ligand 1 (PD-L1) Biomarker-Positive (Combined Positive Score [CPS] ≥10)
- Primary outcome: OS in Participants With ESCC
- Primary outcome: OS in Participants Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10)
- Primary outcome: OS in All Participants
- Primary outcome: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) As Assessed By Investigator in Participants With ESCC
- Primary outcome: PFS Per RECIST 1.1 As Assessed By Investigator in Participants Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10)
- Primary outcome: PFS Per RECIST 1.1 As Assessed By Investigator in All Participants

## Indexed commentary on KEYNOTE-590 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 44
- Podcasts: 21
- YouTube: 15

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=keynote-590-nct03189719

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03189719", "email": "<work email>"}; the inbox owner confirms by the emailed link.